TRDA Entrada Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1689375 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.5%
TTM net income YoY-56.0%
TTM EPS YoY-49.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,303.8%
Net margin-4,058.0%
FCF margin-3,428.1%
EBITDA margin-4,223.6%
Returns
ROE-59.9%
ROA-47.5%
ROIC (approx.)-82.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.00x
Current ratio7.85x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $25.42M | $210.78M | $129.01M | — | — |
| R&D expense | $142.27M | $125.31M | $99.88M | $66.61M | $35.93M |
| SG&A expense | $41.05M | $38.47M | $32.29M | $30.64M | $15.20M |
| Operating income | -$157.90M | $47.01M | -$3.16M | -$97.25M | -$51.13M |
| Income tax | $924,000 | $859,000 | $18.74M | $0 | $0 |
| Net income | -$143.75M | $65.63M | -$6.68M | -$94.62M | -$51.16M |
| EBITDA | -$153.80M | $50.78M | -$321,000 | -$95.35M | -$50.01M |
| EPS (basic) | -3.47 | 1.76 | -0.20 | -3.02 | -8.16 |
| EPS (diluted) | -3.47 | 1.68 | -0.20 | -3.02 | -8.16 |
| Weighted avg. shares (diluted) | 41.37M | 39.00M | 33.05M | 31.29M | 6.27M |
| Balance sheet | |||||
| Cash & equivalents | $90.39M | $105.16M | $71.55M | $49.11M | $291.06M |
| Short-term investments | — | — | — | — | $0 |
| Current assets | $306.25M | $440.04M | $369.77M | $209.88M | $298.70M |
| PP&E, net | $7.31M | $10.93M | $11.19M | $7.68M | $6.26M |
| Total assets | $377.38M | $526.32M | $469.19M | $252.06M | $305.83M |
| Current liabilities | $24.45M | $39.48M | $158.80M | $21.97M | $6.72M |
| Total liabilities | $71.25M | $97.64M | $226.83M | $39.50M | $7.12M |
| Shareholders' equity | $306.13M | $428.68M | $242.36M | $212.55M | $298.72M |
| Shares outstanding | 38.28M | 37.57M | 33.44M | 31.39M | 31.22M |
| Cash flow statement | |||||
| Operating cash flow | -$128.51M | -$41.56M | $139.80M | -$93.79M | -$50.86M |
| Capital expenditure | $1.04M | $3.16M | $5.61M | $2.89M | $4.58M |
| Free cash flow | -$129.55M | -$44.72M | $134.19M | -$96.67M | -$55.44M |
| Investing cash flow | $116.81M | -$27.80M | -$138.40M | -$148.65M | -$4.58M |
| Financing cash flow | $887,000 | $102.96M | $21.04M | $479,000 | $307.46M |
| Depreciation & amortization | $4.10M | $3.77M | $2.84M | $1.90M | $1.12M |
| Stock-based compensation | $19.61M | $17.91M | $13.11M | $9.89M | $2.53M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.